Beta Bionics Inc. Common Stock (NASDAQ: BBNX)
53 Days left to seek lead plaintiff status.
The complaint alleges that the Defendants made false and misleading statements to the market about the Company’s automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (“iLet”).